Table 1. Parameters used in the model.

Parameters		Estimate	Source	Ref	Level of evidence
Infection related events
Daily probability CR-BSI	Day 1–5	0.004	database & Q–E study	[22] [21]	1
	Day 6–15	0.009
	Day 16–30	0.020
RR mortality CR-BSI		1.06	Q–E study	[1]	2
Daily probability catheter removal		time varying	Q–E study	[21]	2
Baseline mortality (probabilities)
ICU		0.098	data linkage study	[24]	2
Hospital		0.069
Annual post-discharge	Year 1	0.050
	Year 2–3	0.027
	Year 4–5	0.028
	Year 6–10	0.037
	Year 11–15	0.042
Underlying annual mortality	45–64 yrs	0.004	national statistics	[25]	1
	65–84 yrs	0.030
	85+ yrs	0.140
Utilities
ICU		0.66	elicitation study (EQ-5D)	[26]	3
Population norms	50–59 yrs	0.80	population based survey	[28]	3
	60–69 yrs	0.79
	70–79 yrs	0.75
	80+ yrs	0.66
Cost of CR-BSI
Extra days ICU		2.41	Q–E study	[23]	2
ICU bed-day (2006 AUD)		3,021	costing study	[30]	4
Extra days hospital		7.54	Q–E study	[23]	2
Hospital bed-day (2006 AUD)		843	prior economic evaluation	[31]	3
Diagnostics CR-BSI (2006 AUD)		101.7	health system database	-	1
Treatment CR-BSI (2006 AUD)		591.3
Effectiveness infection control (RR)
CH/SSD catheter		0.66	meta-analysis	[12]	1+
MR catheter		0.39
Bundle		0.34	Q–E study	[33]	2
Additional cost infection control (per catheter; 2006 AUD)
CH/SSD catheter		11.64	health system database	-	1
MR catheter		59.36
Bundle		unknown	-	-	6

Abbreviations: s.e. standard error; CR-BSI catheter related bloodstream infection; ICU intensive care unit; Q–E quasi-experimental; AUD Australian dollar; ec. eval'n economic evaluation; CH/SSD chlorhexidine & silver sulfadiazine; (int/ext) internal & external coating; SPC silver, platinum & carbon; MR minocycline & rifampicin; popul'n population; per comm. personal communication; A-CVC antimicrobial central venous catheter; RR relative risk.